Multiagent PET for risk characterization in sarcoma

Janet F. Eary, Jeanne Link, Mark Muzi, Ernest U. Conrad, David A. Mankoff, Jedediah K. White, Kenneth Krohn

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

A major goal of molecular imaging in cancer is to evaluate patient tumors for risk of treatment resistance and poor outcome using biologically specific PET agents. This approach was investigated using a multiagent imaging protocol for which patients were imaged in a single session to minimize changes in tumor parameters caused by multiple-day and -setting observation differences. Methods: We present data from a pilot study in 10 soft-tissue sarcoma patients imaged with 11C-thymidine for cellular proliferation, 18F- fluoromisonidazole (FMISO) for tissue hypoxia, and 11C-verapamil for P-glycoprotein activity, in comparison with 15O-water for blood flow and 11C-CO2 for metabolite analysis and 18F-FDG clinical scans. Several patients underwent repeated imaging after adriamycin-based chemotherapy. Results: Quantitative imaging results showed that tumor uptake parameters vary between patients and with respect to each other in individual patients, suggesting that each patient's tumor biologic profile is unique. Specific tumor characteristics such as variable cellular proliferation, hypoxic volume, and upregulated P-glycoprotein activity were identified. Conclusion: This study shows that multiagent PET is feasible and yields unique and potentially complementary biologic information on individual tumors.

Original languageEnglish (US)
Pages (from-to)541-546
Number of pages6
JournalJournal of Nuclear Medicine
Volume52
Issue number4
DOIs
StatePublished - Apr 1 2011
Externally publishedYes

Fingerprint

Sarcoma
Neoplasms
P-Glycoprotein
Cell Proliferation
Molecular Imaging
Fluorodeoxyglucose F18
Verapamil
Doxorubicin
Thymidine
Observation
Drug Therapy
Water

Keywords

  • 11C-thymidine
  • 11C-verapamil
  • FMIS.O.
  • PE.T.
  • Sarcoma

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Eary, J. F., Link, J., Muzi, M., Conrad, E. U., Mankoff, D. A., White, J. K., & Krohn, K. (2011). Multiagent PET for risk characterization in sarcoma. Journal of Nuclear Medicine, 52(4), 541-546. https://doi.org/10.2967/jnumed.110.083717

Multiagent PET for risk characterization in sarcoma. / Eary, Janet F.; Link, Jeanne; Muzi, Mark; Conrad, Ernest U.; Mankoff, David A.; White, Jedediah K.; Krohn, Kenneth.

In: Journal of Nuclear Medicine, Vol. 52, No. 4, 01.04.2011, p. 541-546.

Research output: Contribution to journalArticle

Eary, JF, Link, J, Muzi, M, Conrad, EU, Mankoff, DA, White, JK & Krohn, K 2011, 'Multiagent PET for risk characterization in sarcoma', Journal of Nuclear Medicine, vol. 52, no. 4, pp. 541-546. https://doi.org/10.2967/jnumed.110.083717
Eary JF, Link J, Muzi M, Conrad EU, Mankoff DA, White JK et al. Multiagent PET for risk characterization in sarcoma. Journal of Nuclear Medicine. 2011 Apr 1;52(4):541-546. https://doi.org/10.2967/jnumed.110.083717
Eary, Janet F. ; Link, Jeanne ; Muzi, Mark ; Conrad, Ernest U. ; Mankoff, David A. ; White, Jedediah K. ; Krohn, Kenneth. / Multiagent PET for risk characterization in sarcoma. In: Journal of Nuclear Medicine. 2011 ; Vol. 52, No. 4. pp. 541-546.
@article{e86575306d03468984b81beb80737b5b,
title = "Multiagent PET for risk characterization in sarcoma",
abstract = "A major goal of molecular imaging in cancer is to evaluate patient tumors for risk of treatment resistance and poor outcome using biologically specific PET agents. This approach was investigated using a multiagent imaging protocol for which patients were imaged in a single session to minimize changes in tumor parameters caused by multiple-day and -setting observation differences. Methods: We present data from a pilot study in 10 soft-tissue sarcoma patients imaged with 11C-thymidine for cellular proliferation, 18F- fluoromisonidazole (FMISO) for tissue hypoxia, and 11C-verapamil for P-glycoprotein activity, in comparison with 15O-water for blood flow and 11C-CO2 for metabolite analysis and 18F-FDG clinical scans. Several patients underwent repeated imaging after adriamycin-based chemotherapy. Results: Quantitative imaging results showed that tumor uptake parameters vary between patients and with respect to each other in individual patients, suggesting that each patient's tumor biologic profile is unique. Specific tumor characteristics such as variable cellular proliferation, hypoxic volume, and upregulated P-glycoprotein activity were identified. Conclusion: This study shows that multiagent PET is feasible and yields unique and potentially complementary biologic information on individual tumors.",
keywords = "11C-thymidine, 11C-verapamil, FMIS.O., PE.T., Sarcoma",
author = "Eary, {Janet F.} and Jeanne Link and Mark Muzi and Conrad, {Ernest U.} and Mankoff, {David A.} and White, {Jedediah K.} and Kenneth Krohn",
year = "2011",
month = "4",
day = "1",
doi = "10.2967/jnumed.110.083717",
language = "English (US)",
volume = "52",
pages = "541--546",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "4",

}

TY - JOUR

T1 - Multiagent PET for risk characterization in sarcoma

AU - Eary, Janet F.

AU - Link, Jeanne

AU - Muzi, Mark

AU - Conrad, Ernest U.

AU - Mankoff, David A.

AU - White, Jedediah K.

AU - Krohn, Kenneth

PY - 2011/4/1

Y1 - 2011/4/1

N2 - A major goal of molecular imaging in cancer is to evaluate patient tumors for risk of treatment resistance and poor outcome using biologically specific PET agents. This approach was investigated using a multiagent imaging protocol for which patients were imaged in a single session to minimize changes in tumor parameters caused by multiple-day and -setting observation differences. Methods: We present data from a pilot study in 10 soft-tissue sarcoma patients imaged with 11C-thymidine for cellular proliferation, 18F- fluoromisonidazole (FMISO) for tissue hypoxia, and 11C-verapamil for P-glycoprotein activity, in comparison with 15O-water for blood flow and 11C-CO2 for metabolite analysis and 18F-FDG clinical scans. Several patients underwent repeated imaging after adriamycin-based chemotherapy. Results: Quantitative imaging results showed that tumor uptake parameters vary between patients and with respect to each other in individual patients, suggesting that each patient's tumor biologic profile is unique. Specific tumor characteristics such as variable cellular proliferation, hypoxic volume, and upregulated P-glycoprotein activity were identified. Conclusion: This study shows that multiagent PET is feasible and yields unique and potentially complementary biologic information on individual tumors.

AB - A major goal of molecular imaging in cancer is to evaluate patient tumors for risk of treatment resistance and poor outcome using biologically specific PET agents. This approach was investigated using a multiagent imaging protocol for which patients were imaged in a single session to minimize changes in tumor parameters caused by multiple-day and -setting observation differences. Methods: We present data from a pilot study in 10 soft-tissue sarcoma patients imaged with 11C-thymidine for cellular proliferation, 18F- fluoromisonidazole (FMISO) for tissue hypoxia, and 11C-verapamil for P-glycoprotein activity, in comparison with 15O-water for blood flow and 11C-CO2 for metabolite analysis and 18F-FDG clinical scans. Several patients underwent repeated imaging after adriamycin-based chemotherapy. Results: Quantitative imaging results showed that tumor uptake parameters vary between patients and with respect to each other in individual patients, suggesting that each patient's tumor biologic profile is unique. Specific tumor characteristics such as variable cellular proliferation, hypoxic volume, and upregulated P-glycoprotein activity were identified. Conclusion: This study shows that multiagent PET is feasible and yields unique and potentially complementary biologic information on individual tumors.

KW - 11C-thymidine

KW - 11C-verapamil

KW - FMIS.O.

KW - PE.T.

KW - Sarcoma

UR - http://www.scopus.com/inward/record.url?scp=79954623284&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79954623284&partnerID=8YFLogxK

U2 - 10.2967/jnumed.110.083717

DO - 10.2967/jnumed.110.083717

M3 - Article

C2 - 21421714

AN - SCOPUS:79954623284

VL - 52

SP - 541

EP - 546

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 4

ER -